

Zelboraf® (vemurafenib) - New indication

- On November 6, 2017, the <u>FDA announced</u> the approval of <u>Genentech's Zelboraf (vemurafenib)</u> for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation.
 - Zelboraf is also approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
 - Zelboraf is not indicated for treatment of patients with wild-type BRAF melanoma.
- ECD is a slow-growing blood cancer that originates in the bone marrow. ECD causes an increased production of histiocytes, a type of white blood cell, which can result in tumors infiltrating organs and tissues.
 - ECD is estimated to affect 600 700 patients worldwide. Approximately 54% of patients with ECD have the BRAF V600 mutation.
- The new indication for Zelboraf was approved based on a single-arm trial in 22 patients (≥ 16 years old) with BRAF V600 mutation-positive ECD. The primary endpoint was the objective response rate (ORR).
 - In the trial, the ORR was 54.5% (95% CI: 32.2, 75.6). In addition, 50% of the patients achieved a partial response and 4.5% of patients achieved a complete response.
- In the ECD trial, the most common adverse reactions (> 50%) with Zelboraf use were arthralgia, maculo-papular rash, alopecia, fatigue, prolonged QT interval, and skin papilloma.
- In patients with ECD, the recommended dosage of Zelboraf is 960 mg (four 240 mg tablets) orally every 12 hours until disease progression or toxicity.
 - For the dosage of Zelboraf in melanoma, please refer to the drug label.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.